Advanced Solid Tumors: Targeted Therapy Study

We are testing new targeted treatments for patients with advanced solid tumors to see how well they work for specific tumor types. This study aims to enhance personalized medicine in cancer treatment.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Tecentriq
Tecentriq is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Amivantamab
Amivantamab is a substance that targets specific proteins on certain lung cancer cells to help control advanced non-small-cell lung cancer with EGFR exon 20 mutations.
Atezolizumab
Atezolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-L1.
Futibatinib
Futibatinib is a substance that targets specific FGFR gene changes to treat certain cancers, especially advanced bile duct cancer.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Jnj-61186372

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Institut Gustave Roussy
Medical Oncology
Villejuif, France
Technische Universitaet Dresden
Medical Oncology
Dresden, Germany
Universitaetsklinikum Heidelberg AöR
Hematology
Heidelberg, Germany

Sponsor: Vall D Hebron Institute Of Oncology
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.